Stocks › AGIO
AGIOS PHARMACEUTICALS, INC.
AGIO·Nasdaq·
United States·USD
United States·USD$31.72
+0.47 (+1.50%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
AGIO
AGIOS PHARMACEUTICALS, INC. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
AGIOS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of AGIO by members of U.S. Congress · 8 on record · 3 in the last 12 months
Whale Activity
Position changes in AGIO reported for 2026-06-30 by 12 tracked institutional filers
- Increased6
- New1
- Held0
- Decreased0
- Closed1
- No prior filing4
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 6.5M | $239.6M | increased |
| D. E. Shaw & Co., Inc. | 3.1M | $115.3M | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2.9M | $107.6M | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.7M | $99.5M | increased |
| CITADEL ADVISORS LLC | 732.7K | $27.2M | increased |
| TWO SIGMA INVESTMENTS, LP | 536.4K | $19.9M | increased |
| Point72 Asset Management, L.P. | 506.3K | $18.8M | new |
| Palo Alto Investors LP | 213.6K | $7.9M | — |
| Tetragon Partners GP Ltd | 205.6K | $7.6M | — |
| Knott David M Jr | 95.1K | $3.5M | — |
| Seven Fleet Capital Management LP | 56.9K | $2.1M | — |
| Millennium Management LLC | 0 | $0 | closed |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by AGIO insiders, by quarter · Form 4
Recent Insider Transactions
1,260 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Gheuens SarahChief Medical Officer | Sale | −30.0K | $30.48 | $914K | Aug 4, 2026 | Form 4 ↗ |
| Gheuens SarahChief Medical Officer | Sale | −4,007 | $37.56 | $151K | Jul 1, 2026 | Form 4 ↗ |
| Ballal Rahul D.Director | Option exercise | +2,816 | $0.00 | $0 | Jun 18, 2026 | Form 4 ↗ |
| CAPELLO JEFFREY DDirector | Option exercise | +2,816 | $0.00 | $0 | Jun 18, 2026 | Form 4 ↗ |
| Foster-Cheek Kaye IDirector | Option exercise | +2,816 | $0.00 | $0 | Jun 18, 2026 | Form 4 ↗ |
| FOUSE JACQUALYN ADirector | Option exercise | +2,816 | $0.00 | $0 | Jun 18, 2026 | Form 4 ↗ |
| Ho MaykinDirector | Option exercise | +2,816 | $0.00 | $0 | Jun 18, 2026 | Form 4 ↗ |
| Owen Adams CatherineDirector | Option exercise | +2,816 | $0.00 | $0 | Jun 18, 2026 | Form 4 ↗ |
| Scadden DavidDirector | Option exercise | +2,816 | $0.00 | $0 | Jun 18, 2026 | Form 4 ↗ |
| Smith CynthiaDirector | Option exercise | +2,816 | $0.00 | $0 | Jun 18, 2026 | Form 4 ↗ |
| Owen Adams CatherineDirector | Option exercise | +1,976 | $0.00 | $0 | Jun 13, 2026 | Form 4 ↗ |
| CAPELLO JEFFREY DDirector | Option exercise | +1,976 | $0.00 | $0 | Jun 13, 2026 | Form 4 ↗ |
| Burns James WilliamChief Legal Officer | Sale | −3,280 | $34.71 | $114K | Apr 2, 2026 | Form 4 ↗ |
| Burns James WilliamChief Legal Officer | Option exercise | +8,500 | $0.00 | $0 | Apr 2, 2026 | Form 4 ↗ |
| Gheuens SarahChief Medical Officer | Sale | −2,940 | $34.71 | $102K | Apr 2, 2026 | Form 4 ↗ |
| Gheuens SarahChief Medical Officer | Option exercise | +8,500 | $0.00 | $0 | Apr 2, 2026 | Form 4 ↗ |
| Jones CeciliaChief Financial Officer | Sale | −3,141 | $34.71 | $109K | Apr 2, 2026 | Form 4 ↗ |
| Jones CeciliaChief Financial Officer | Option exercise | +8,500 | $0.00 | $0 | Apr 2, 2026 | Form 4 ↗ |
| Milanova TsvetaChief Commercial Officer | Sale | −3,262 | $34.71 | $113K | Apr 2, 2026 | Form 4 ↗ |
| Milanova TsvetaChief Commercial Officer | Option exercise | +8,500 | $0.00 | $0 | Apr 2, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding AGIO · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 2.0M | $74.4M | 0.69% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.9M | $70.1M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 1.5M | $57.1M | 0.07% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 1.4M | $50.6M | 0.03% | Jun 30, 2026 |
| Nomura Small Cap Core Fund Delaware Group Equity Funds V | 1.1M | $33.7M | 0.61% | May 29, 2026 |
| VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS | 788.7K | $29.3M | 0.06% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 684.0K | $25.4M | 0.03% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 609.5K | $20.6M | 0.22% | Mar 31, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 646.3K | $19.4M | 0.06% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF iShares Trust | 520.3K | $19.3M | 0.13% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list AGIO's shares (CUSIP 00847X104), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- Farallon Capital F5 Master I, L.P.SCHEDULE 13G/A · passive (13G) · 0 shares0.0%
Aug 3, 2026 · ↗ - Farallon Capital (AM) Investors, L.P.SCHEDULE 13G/A · passive (13G) · 0 shares0.0%
Aug 3, 2026 · ↗ - Farallon Capital Offshore Investors II, L.P.SCHEDULE 13G/A · passive (13G) · 0 shares0.0%
Aug 3, 2026 · ↗ - Four Crossings Institutional Partners V, L.P.SCHEDULE 13G/A · passive (13G) · 0 shares0.0%
Aug 3, 2026 · ↗ - Farallon Capital Institutional Partners III, L.P.SCHEDULE 13G/A · passive (13G) · 0 shares0.0%
Aug 3, 2026 · ↗ - Farallon Capital Institutional Partners II, L.P.SCHEDULE 13G/A · passive (13G) · 0 shares0.0%
Aug 3, 2026 · ↗ - Farallon Capital Institutional Partners, L.P.SCHEDULE 13G/A · passive (13G) · 0 shares0.0%
Aug 3, 2026 · ↗ - Wehrly, Mark C.SCHEDULE 13G/A · passive (13G) · 5.9M shares9.9%
Aug 3, 2026 · ↗ - Warren, John R.SCHEDULE 13G/A · passive (13G) · 5.9M shares9.9%
Aug 3, 2026 · ↗ - Spokes, Andrew J. M.SCHEDULE 13G/A · passive (13G) · 5.9M shares9.9%
Aug 3, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming agios pharmaceuticals as client
- AGIOS PHARMACEUTICALSAGIOS PHARMACEUTICALS · 2026 Q2 · HCR, MED, MMM$30K
Filing ↗ - JEFFREY J. KIMBELL & ASSOCIATES, INC.AGIOS PHARMACEUTICALS, INC. · 2026 Q2 · HCR$10K
Filing ↗ - GRIDIRON PUBLIC AFFAIRS, LLCAGIOS PHARMACEUTICALS · 2026 Q2 · HCR$10K
Filing ↗ - GRIDIRON PUBLIC AFFAIRS, LLCAGIOS PHARMACEUTICALS · 2026 Q2 · HCR—
Filing ↗ - JEFFREY J. KIMBELL & ASSOCIATES, INC.AGIOS PHARMACEUTICALS, INC. · 2026 Q1 · HCR$10K
Filing ↗
Government Contracts
Federal awards to agios pharmaceuticals · USAspending
$73KAwarded · 1 contract on record
- Department of Veterans AffairsPHARMACEUTICAL AQVESME - 3 MONTH SUPPLY.$73K
Jul 15, 2026 · ↗
U.S. Patents
Recent USPTO applications naming AGIOS PHARMACEUTICALS, INC.
No USPTO patent applications found for AGIOS PHARMACEUTICALS, INC..
Annual Financials
From AGIO's 10-K filings · XBRL
No annual XBRL figures on record for AGIO. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
No stock splits in AGIO's price history.
About AGIOS PHARMACEUTICALS, INC.
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersCAMBRIDGE, MA
IncorporatedDE
SEC CIK0001439222 ↗
Former namesAGIOS PHARMACEUTICALS INC